Insider Selling: Zimmer Biomet (NYSE:ZBH) Insider Sells $295,050.00 in Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $93.47 on Friday. The firm has a fifty day simple moving average of $95.54 and a 200-day simple moving average of $91.52. The company has a market capitalization of $17.83 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 1.75 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $106.88. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the firm posted $2.07 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is 23.36%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of recent analyst reports. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research note on Thursday, August 6th. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Citigroup reduced their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Sanford C. Bernstein lifted their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $104.42.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. DV Equities LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at approximately $25,000. Tacita Capital Inc acquired a new position in Zimmer Biomet in the second quarter worth $26,000. Ancora Advisors LLC acquired a new position in Zimmer Biomet in the second quarter worth $29,000. Monetary Solutions Ltd bought a new stake in Zimmer Biomet during the fourth quarter valued at $30,000. Finally, Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $31,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.